Cargando…

Prevalence and treatment of vitamin K deficiency in paediatric patients with recessive dystrophic epidermolysis bullosa‐severe subtype

INTRODUCTION: Patients with recessive dystrophic epidermolysis bullosa‐severe subtype (RDEB‐S) are at risk of vitamin K deficiency, potentially causing abnormal clotting, excessive bleeding, poor bone metabolism and abnormal vascular calcification. This study quantifies vitamin K deficiency prevalen...

Descripción completa

Detalles Bibliográficos
Autores principales: Yerlett, N., Petrof, G., Holsgrove, K., Martinez, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060092/
https://www.ncbi.nlm.nih.gov/pubmed/35664980
http://dx.doi.org/10.1002/ski2.14
_version_ 1784698445782581248
author Yerlett, N.
Petrof, G.
Holsgrove, K.
Martinez, A.
author_facet Yerlett, N.
Petrof, G.
Holsgrove, K.
Martinez, A.
author_sort Yerlett, N.
collection PubMed
description INTRODUCTION: Patients with recessive dystrophic epidermolysis bullosa‐severe subtype (RDEB‐S) are at risk of vitamin K deficiency, potentially causing abnormal clotting, excessive bleeding, poor bone metabolism and abnormal vascular calcification. This study quantifies vitamin K deficiency prevalence in this cohort and identifies potential risk‐factors to prevent deficiency. METHODS: Patients with RDEB‐S who attended the EB service between 2014 and 2020 were included. Serum vitamin K and PIVKAII were measured as part of the usual nutritional blood screen. Dietetic and medical notes were reviewed to establish: antibiotic use, enteral feed intake and micronutrient supplementation. RESULTS: A total of 16/25 64% (10/16 female), of children aged 22–180 months, had serum vitamin K and PIVKAII analysed. Six of sixteen (37.5%) patients had vitamin K deficiency requiring supplementation. Two of six (33.3%) normalized serum vitamin K after 12 weeks supplementation with oral menadiol diphosphate. Four of six (66.6%) await retesting following supplementation. Six of six (100%) patients with vitamin K deficiency were not consuming a gastrostomy/sip feed. Nine of ten (90%) patients with sufficient vitamin K levels were consuming either; more than 200 ml prescribed sip feed or more than 400–800 ml gastrostomy feed daily (containing 5.9–11 µg/100 ml vitamin K). Patients who were consuming either more than 200 ml prescribed sip feed or more than 400–800 ml gastrostomy feed daily (containing 5.9–11 µg/100 ml vitamin K) were significantly less likely to suffer from vitamin K deficiency (0.08 odds ratio [(1/7)/(5/3)] with significance level p = 0.0342 [95% CI: 0.0074–0.8275]). Sixteen of sixteen (100%) received antibiotics (range 0–4 courses/year; median, 3; IQR, 3). Patients with the most frequent antibiotics (n = 4) had normal vitamin K and PIVKAII levels if they consumed a minimum of 200 ml prescribed sip feed or 400–800 ml gastrostomy feed daily. Sixteen of sixteen (100%) patients took a multivitamin/mineral supplement; none contained vitamin K. SUMMARY: The prevalence of vitamin K deficiency is 37.5% in this cohort. Patients whom were not consuming gastrostomy/sip feeds of at least 200 ml daily were at greatest risk of vitamin K deficiency. Patients on a micronutrient supplement remain at risk of vitamin K deficiency, as most contain no vitamin K. Prescribing a vitamin/mineral supplement that contains vitamin K is recommended. Twelve‐week supplementation of oral vitamin K (5 mg/day for 1–10 years and 10 mg/day for 12–17 years) adequately improved stores.
format Online
Article
Text
id pubmed-9060092
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90600922022-06-04 Prevalence and treatment of vitamin K deficiency in paediatric patients with recessive dystrophic epidermolysis bullosa‐severe subtype Yerlett, N. Petrof, G. Holsgrove, K. Martinez, A. Skin Health Dis Original Articles INTRODUCTION: Patients with recessive dystrophic epidermolysis bullosa‐severe subtype (RDEB‐S) are at risk of vitamin K deficiency, potentially causing abnormal clotting, excessive bleeding, poor bone metabolism and abnormal vascular calcification. This study quantifies vitamin K deficiency prevalence in this cohort and identifies potential risk‐factors to prevent deficiency. METHODS: Patients with RDEB‐S who attended the EB service between 2014 and 2020 were included. Serum vitamin K and PIVKAII were measured as part of the usual nutritional blood screen. Dietetic and medical notes were reviewed to establish: antibiotic use, enteral feed intake and micronutrient supplementation. RESULTS: A total of 16/25 64% (10/16 female), of children aged 22–180 months, had serum vitamin K and PIVKAII analysed. Six of sixteen (37.5%) patients had vitamin K deficiency requiring supplementation. Two of six (33.3%) normalized serum vitamin K after 12 weeks supplementation with oral menadiol diphosphate. Four of six (66.6%) await retesting following supplementation. Six of six (100%) patients with vitamin K deficiency were not consuming a gastrostomy/sip feed. Nine of ten (90%) patients with sufficient vitamin K levels were consuming either; more than 200 ml prescribed sip feed or more than 400–800 ml gastrostomy feed daily (containing 5.9–11 µg/100 ml vitamin K). Patients who were consuming either more than 200 ml prescribed sip feed or more than 400–800 ml gastrostomy feed daily (containing 5.9–11 µg/100 ml vitamin K) were significantly less likely to suffer from vitamin K deficiency (0.08 odds ratio [(1/7)/(5/3)] with significance level p = 0.0342 [95% CI: 0.0074–0.8275]). Sixteen of sixteen (100%) received antibiotics (range 0–4 courses/year; median, 3; IQR, 3). Patients with the most frequent antibiotics (n = 4) had normal vitamin K and PIVKAII levels if they consumed a minimum of 200 ml prescribed sip feed or 400–800 ml gastrostomy feed daily. Sixteen of sixteen (100%) patients took a multivitamin/mineral supplement; none contained vitamin K. SUMMARY: The prevalence of vitamin K deficiency is 37.5% in this cohort. Patients whom were not consuming gastrostomy/sip feeds of at least 200 ml daily were at greatest risk of vitamin K deficiency. Patients on a micronutrient supplement remain at risk of vitamin K deficiency, as most contain no vitamin K. Prescribing a vitamin/mineral supplement that contains vitamin K is recommended. Twelve‐week supplementation of oral vitamin K (5 mg/day for 1–10 years and 10 mg/day for 12–17 years) adequately improved stores. John Wiley and Sons Inc. 2021-03-31 /pmc/articles/PMC9060092/ /pubmed/35664980 http://dx.doi.org/10.1002/ski2.14 Text en © 2021 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Yerlett, N.
Petrof, G.
Holsgrove, K.
Martinez, A.
Prevalence and treatment of vitamin K deficiency in paediatric patients with recessive dystrophic epidermolysis bullosa‐severe subtype
title Prevalence and treatment of vitamin K deficiency in paediatric patients with recessive dystrophic epidermolysis bullosa‐severe subtype
title_full Prevalence and treatment of vitamin K deficiency in paediatric patients with recessive dystrophic epidermolysis bullosa‐severe subtype
title_fullStr Prevalence and treatment of vitamin K deficiency in paediatric patients with recessive dystrophic epidermolysis bullosa‐severe subtype
title_full_unstemmed Prevalence and treatment of vitamin K deficiency in paediatric patients with recessive dystrophic epidermolysis bullosa‐severe subtype
title_short Prevalence and treatment of vitamin K deficiency in paediatric patients with recessive dystrophic epidermolysis bullosa‐severe subtype
title_sort prevalence and treatment of vitamin k deficiency in paediatric patients with recessive dystrophic epidermolysis bullosa‐severe subtype
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060092/
https://www.ncbi.nlm.nih.gov/pubmed/35664980
http://dx.doi.org/10.1002/ski2.14
work_keys_str_mv AT yerlettn prevalenceandtreatmentofvitaminkdeficiencyinpaediatricpatientswithrecessivedystrophicepidermolysisbullosaseveresubtype
AT petrofg prevalenceandtreatmentofvitaminkdeficiencyinpaediatricpatientswithrecessivedystrophicepidermolysisbullosaseveresubtype
AT holsgrovek prevalenceandtreatmentofvitaminkdeficiencyinpaediatricpatientswithrecessivedystrophicepidermolysisbullosaseveresubtype
AT martineza prevalenceandtreatmentofvitaminkdeficiencyinpaediatricpatientswithrecessivedystrophicepidermolysisbullosaseveresubtype